Optic Neuritis Treatment Market size was over USD 232.1 Million in 2023 and is poised to reach USD 465.54 Million by the end of 2036, growing at around 5.5% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of optic neuritis treatment is assessed at USD 243.59 Million. The reason behind the growth is impelled by rising incidences of bacterial infections across the globe. Optic neuritis is frequently idiopathic and can occur in combination with infectious disorders such as Lyme disease, and syphilis, since the infection may prompt the immune system to attack the optic nerve as if it were a foreign intruder. As a result, the treatment for optic neuritis becomes crucial to prevent potential optic nerve damage.
The significant increment in the global geriatric population is believed to fuel market growth. For instance, the elderly population is more susceptible to age-related eye diseases such as cataracts, and glaucoma, which may lead to optic neuritis. Ischemic optic neuropathy, which is more common, mostly affects older persons and has an impact on the visual acuity of adults and seniors. Therefore, a significant increment in the global geriatric population is fueling the market. According to estimates, the number of individuals in the world who are 60 or older will increase to more than 2 billion by 2050.
Growth Drivers
Challenges
|
Base Year |
2023 |
|
Forecast Year |
2024-2036 |
|
CAGR |
5.5% |
|
Base Year Market Size (2023) |
USD 232.1 Million |
|
Forecast Year Market Size (2036) |
USD 465.54 Million |
|
Regional Scope |
|
End-User (Ambulatory Surgery Centers, Clinics, Hospitals)
The hospital segment in the optic neuritis treatment market is estimated to gain a robust revenue share in the coming years owing to the availability of medical device testing, medical professionals in a single place, and a notable patient pool. In addition, hospitals have specialized departments which have the expertise and better resources to provide quality care for optic neuritis patients. Advanced diagnostic tools and around-the-clock medical professionals are also easily available on hospital premises, aiding in the accurate and timely diagnosis of optic neuritis.
Treatment Type (Surgery, Pharmacological)
Optic neuritis treatment market from the pharmacological segment is set to garner a notable share in the near future since pharmacological treatments such as the usage of steroid medications are used to lessen inflammation in the optic nerve and hasten the healing of ocular neuritis. The treatment also includes corticosteroid drugs used to treat optic neuritis, which has proved its efficiency for decades. For instance, for improving visual outcomes in optic neuritis, the use of an oral high-dose corticosteroid is just as effective as a high-dose intravenous corticosteroid. Besides this, pharmacological treatment includes disease-modifying therapies that are widely used to treat optic neuritis cases associated with multiple sclerosis.
Our in-depth analysis of the global market includes the following segments:
|
Treatment Type |
|
|
Indication |
|
|
End-User |
|
North American Market Forecast
Optic neuritis treatment market in North America is predicted to account for the largest share of 35% by the end of 2036 impelled by the higher adoption of steroids. As a result, it may increase access to steroid treatment for optic neuritis in the region. More than 3% of high school seniors in the US have used steroids at least once in their lifetime, and almost half a million youngsters use them annually
APAC Market Statistics
The Asia Pacific optic neuritis treatment market is estimated to be the second largest, during the forecast timeframe led by the growing prevalence of herpes, mumps, and measles. Growing cases of these viral infections may potentially result in optic neuritis in a higher number of individuals in the region. Since it is a secondary condition resulting from the immune response to the viral infection which can cause inflammation in the optic nerve. For instance, in countries like Sri Lanka, China, and others, more than 95% of children up to 23 months old were observed to be immunized against measles.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?